Sign inJoin waitlistJoin the waitlist

Ruth Karron

Director, Center for Immunization Research · Univ of Maryland Sch of Med

Credentials: · ·

History

Center for Immunization Research · Univ of Maryland Sch of Med
Present
Johns Hopkins Bloomberg School of Public Health
Present
Univ of Maryland Sch of Med
Present

Infectious Disease
Internal Medicine

Research

Safety and immunogenicity trial in adult volunteers of a human papillomavirus 16 L1 virus-like particle vaccine
Journal of the National Cancer Institute · 2001 · 440 citations
The respiratory syncytial virus vaccine landscape: lessons from the graveyard and promising candidates
Review · The Lancet Infectious Diseases · 2018 · 368 citations
Respiratory syncytial virus (RSV) SH and G proteins are not essential for viral replication in vitro: clinical evaluation and molecular characterization of a cold-passaged,…
Proceedings of the National Academy of Sciences of the United States of America · 1997 · First of 11 authors · Corresponding · 355 citations

KO
Katherine O'Brien
28 papers
Laura Hammitt
24 papers · 1 as a fellow
Donald Thea
19 papers
Karen Kotloff
19 papers
Peter Wright
14 papers
FP
Fernando Polack
11 papers
Coleen Cunningham
10 papers
KS
Kanta Subbarao
10 papers
Kawsar Talaat
10 papers
NB
Niranjan Bhat
10 papers
RB
Robert Belshe
10 papers
Elizabeth McFarland
9 papers

Grants

Task A31: Fungal In Vitro Screening
NIH Office of the Director · N01
Contact PI · $2.4M · University of Texas Hlth Science Center
2019–2026
Biomedical Research Support
National Center for Research Resources · S07
Project lead · Johns Hopkins University

Clinical trials

Study of the Infectivity, Safety and Immunogenicity of Two Recombinant, Live-Attenuated, B/HPIV3 Vectored Vaccines Expressing the Fusion Glycoprotein of HMPV Delivered by Nasal Spray to HPIV3-Seropositive Children 24 to <60 Months of Age
Principal investigator · Completed · Phase 1
National Institute of Allergy and Infectious Diseases (NIAID)
2024–2025
Evaluating the Infectivity, Safety and Immunogenicity of a Recombinant Live-Attenuated Respiratory Syncytial Virus Vaccine, LID/ΔM2-2/1030s, in RSV-Seronegative Infants and Children 6 to 24 Months of Age
Principal investigator · Completed · Phase 1
National Institute of Allergy and Infectious Diseases (NIAID)
2022–2024
Evaluating the Infectivity, Safety and Immunogenicity of Respiratory Syncytial Virus Vaccines, RSV 6120/∆NS1 and RSV 6120/F1/G2/∆NS1, in RSV-Seropositive Children and RSV-Seronegative Infants and Children
Principal investigator · Completed · Phase 1
National Institute of Allergy and Infectious Diseases (NIAID)
2018–2024
Evaluating the Infectivity, Safety, and Immunogenicity of a Respiratory Syncytial Virus Vaccine (RSV 6120/∆NS2/1030s) in RSV-Seropositive Children and RSV-Seronegative Infants and Children
Principal investigator · Completed · Phase 1
National Institute of Allergy and Infectious Diseases (NIAID)
2017–2021